Last reviewed · How we verify
metformin/glimepiride combination
Metformin reduces hepatic glucose production and improves insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion, together lowering blood glucose in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin/glimepiride combination |
|---|---|
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Biguanide/Sulfonylurea combination |
| Target | AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and enhances peripheral glucose uptake and utilization. Glimepiride is a meglitinide-class sulfonylurea that binds to ATP-sensitive potassium channels on pancreatic beta cells, triggering insulin release. The combination addresses both insulin resistance and beta-cell dysfunction in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Headache
- Dizziness
- Lactic acidosis (rare)
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (PHASE4)
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure (PHASE3)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin (NA)
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) (PHASE4)
- Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
- Head-to-head Comparison of Empagliflozin and Dapagliflozin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: